Hypoxia Analysis in Head and/or Neck Cancer

• Status: Recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is the prospective determination of disease-specific and overall survival in head and neck cancer patients who have undergone surgery, correlated to non-invasive methods of measuring tumour hypoxia.

The secondary objective is to define tumour hypoxia using non-invasive methodology.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Marius Gustav Bredell

Criteria

Inclusion Criteria:

• Malignancy in head and/or neck region only

• Interdisciplinary Head and neck tumour board (USZ) confirmed inclusion in the project

• For patients with reproductive potential (e.g. female participants who are surgically sterilised/hysterectomised or post-menopausal for longer than 2 years are not considered as beig of child bearing potential), a willingness to use adequate contraceptive measures to prevent pregnancy during the project.

Exclusion Criteria:

• Pregnant or breastfeeding

• Suffers from claustrophobia

• Known allergy to Pimonidazole

• Participation in a study with an investigational drug within the 30 days preceding and during this project

• Tumour size smaller than 1cm

• Has symptomatic Chronic Obstructive Pulmonary Disease (COPD)

• Patient refuses or is unable to give a written informed consent

• Previous treatment for head and/or neck cancer

• Inability to follow the procedures of the project e.g. due to language problems, psychological disorders, dementia, etc. of the participant.